Dublin, April 21, 2025 (GLOBE NEWSWIRE) -- The "Gastric Neuroendocrine Tumors Market" report has been added to ResearchAndMarkets.com's offering. The gastric neuroendocrine tumor (gNET ...

(MENAFN- GlobeNewsWire - Nasdaq) Market advancements are driven by rising incidences of neuroendocrine tumors, improved diagnostics, and targeted therapies. Key players like Novartis AG and Pfizer ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved Cabometyx ...

A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...

Dublin, April 21, 2025 (GLOBE NEWSWIRE) -- The "Gastric Neuroendocrine Tumors Market" report has been added to ResearchAndMarkets.com's offering. The gastric neuroendocrine tumor (gNET) market, valued ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors, offering a new ...

Consequently, Cabometyx is now the first and only systemic treatment that is FDA-approved for previously treated neuroendocrine tumors regardless of primary tumor site, grade, somatostatin ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

GERMANTOWN, Md., April 16, 2025 /PRNewswire/ -- The HealthWell Foundation ®, an independent non-profit charitable organization that provides financial assistance for underinsured Americans has ...